Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1
about
Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities.The Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesThe structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changesHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateStructure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptaseAnti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptaseSelective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anL-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseStructure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilideMode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerasesRNA-Mediated Gene Duplication and Retroposons: Retrogenes, LINEs, SINEs, and Sequence SpecificityStructure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.Creating a community resource for protein science.Diversity-oriented solid-phase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors.From docking false-positive to active anti-HIV agent.Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoringNucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotranspositionCombinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesSusceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitorsNevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyHuman immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.The "Connection" Between HIV Drug Resistance and RNase HNon-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionHuman immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.
P2860
Q24796883-14B946A6-F997-4EB3-97D6-C1270E9977DDQ27489856-A1EAA8EF-BCB2-421C-8BFD-3BB4E59AEF1AQ27729415-E0CF3271-C5EE-4E8E-8338-0D53247B8121Q27735940-AD148DF1-F1D4-41DE-A378-D4DCEE69728AQ27764900-E383C45B-759B-402E-BF45-A2FD83D147C0Q28250395-07B96584-D814-48DD-BF63-F3C18806EC1DQ28369309-0738B72B-CA84-4600-BBC6-705E147DFE74Q28378745-FDB5C4ED-9631-498F-9E92-53E100B0A52FQ28378760-015E7C93-94D8-45FA-A511-B15C9C4EB386Q28378789-45BF30E5-D88E-4966-852F-1BD91CC27E4EQ28378796-7C402E51-1EDD-41EE-8A1C-93417D5558B6Q28379011-9C8AF16A-C161-456D-B8EA-3C4162C70EBAQ28681782-486D712F-0373-4653-8BFE-73907A30CDB6Q30342229-A9A773E3-54A2-4B1F-909E-A4BF08560CD4Q30421172-64CE66A7-1331-4707-824D-43BA664DA6CEQ33209407-7160BE97-9194-4666-8C03-0B42AC999192Q33301713-7F4E7444-E8AA-4587-A65F-0FAB10362905Q33303221-A17090D4-D5BD-452B-9654-36F9FF51AE89Q33318459-ED715424-AD88-44C8-BC79-F3340F1AC083Q33535654-2CBF8D5F-219F-4999-BE42-271F7A553748Q33757596-7F7F832F-EFAC-4828-9F7E-6F5027D40B3DQ33815628-C720245D-5775-4CAE-82E6-6012A60F2D6DQ33835882-1E58103F-FDB3-4A88-8B12-17A679A1955BQ33850152-6416D053-6885-4ADC-AF5F-A7DC0B1F8FAEQ33851627-A0E3DCF1-EB30-47F3-B903-1D88E7DAFDBDQ33873983-B87B6CBE-445B-473D-B15B-60A9F2FC9CDAQ33892766-A758715B-4901-4452-B5A0-631CB5E763B8Q33935269-2A9794E4-631E-4A26-8DA3-7F94137116A4Q33976004-9282CECB-B3EF-46F1-A251-45576254F8AFQ33980528-4103E71D-443C-4F95-8BAE-D747C8C4C04EQ33987492-2EE3A3B7-B715-4523-9A11-98E5AE270EFDQ34026086-3FE8E68F-4129-460F-A4E9-504AE32C84B0Q34094395-A299D125-4786-4D2B-BF11-AD73B7BF27F6Q34242282-DAF89B28-FE9C-4C7D-8744-E1BD2154211FQ34303603-9999331A-41D4-4B32-B611-4F0CFF8BF43CQ34313605-C7CE15BB-7A9B-441E-B8CB-2588182A8DA9Q34481618-6A79D0DD-5A88-4AD4-9598-49472F09A40BQ35122784-027E23C5-13A6-47A2-A634-E1ED0C627858Q35149625-EADF5EEE-FE5B-43D3-98A9-8A21E8CB73B1Q35185934-DF1BF033-A5EA-4D15-83EF-6DBDB49AE567
P2860
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Structure of the binding site ...... immunodeficiency virus type 1
@ast
Structure of the binding site ...... immunodeficiency virus type 1
@en
Structure of the binding site ...... immunodeficiency virus type 1
@nl
type
label
Structure of the binding site ...... immunodeficiency virus type 1
@ast
Structure of the binding site ...... immunodeficiency virus type 1
@en
Structure of the binding site ...... immunodeficiency virus type 1
@nl
prefLabel
Structure of the binding site ...... immunodeficiency virus type 1
@ast
Structure of the binding site ...... immunodeficiency virus type 1
@en
Structure of the binding site ...... immunodeficiency virus type 1
@nl
P2093
P2860
P3181
P356
P1476
Structure of the binding site ...... immunodeficiency virus type 1
@en
P2093
P2860
P304
P3181
P356
10.1073/PNAS.91.9.3911
P407
P577
1994-04-01T00:00:00Z